Aims-To determine the type of endometrial abnormalities associated with prolonged tamoxifen treatment and to investigate the correlation between tamoxifen dose and any abnormalities detected. Methods-Endometria from 19 prospectively collected breast cancer patients treated with tamoxifen were ascribed a pathological diagnosis and the findings compared with those in a control group matched for age and presentation. The abnormalities were related to cumulative tamoxifen dose. Results-The two asymptomatic treated patients had generalised simple endometrial hyperplasia at necropsy. No endometrial abnormalities were seen at necropsy in the two control cases. Of the 17 patients treated with tamoxifen who underwent surgery for gynaecological symptoms, 11 had hyperplastic endometrial polyps characterised by epithelial metaplasias and patchy periglandular condensation of stroma. Two women had primary endometrial malignancies with myometrial invasion, and three women, one of whom had previously presented with a benign polyp, had an endometrial polyp-cancer on a background of hyperplasia. Endometrial malignancies were confined to women who had taken more than 35 g of tamoxifen. The control group included no endometrial polyp-cancers, only one patient with an endometrial polyp, four women with endometrial hyperplasia and four with primary endometrial malignancy. Conclusions-These findings support a link between prolonged tamoxifen treatment and endometrial malignancy and identify a subgroup of patients-that is, those who have taken more than 35 g of tamoxifen, who may be at increased risk of endometrial cancer.
tamoxifen dose and any abnormalities detected. Methods-Endometria from 19 prospectively collected breast cancer patients treated with tamoxifen were ascribed a pathological diagnosis and the findings compared with those in a control group matched for age and presentation. The abnormalities were related to cumulative tamoxifen dose. Results-The two asymptomatic treated patients had generalised simple endometrial hyperplasia at necropsy. No endometrial abnormalities were seen at necropsy in the two control cases. Of the 17 patients treated with tamoxifen who underwent surgery for gynaecological symptoms, 11 had hyperplastic endometrial polyps characterised by epithelial metaplasias and patchy periglandular condensation of stroma. Two women had primary endometrial malignancies with myometrial invasion, and three women, one of whom had previously presented with a benign polyp, had an endometrial polyp-cancer on a background of hyperplasia. Endometrial malignancies were confined to women who had taken more than 35 g of tamoxifen. The control group included no endometrial polyp-cancers, only one patient with an endometrial polyp, four women with endometrial hyperplasia and four with primary endometrial malignancy. Conclusions-These findings support a link between prolonged tamoxifen treatment and endometrial malignancy and identify a subgroup of patients-that is, those who have taken more than 35 g of tamoxifen, who may be at increased risk of endometrial cancer. The spectrum of pathological findings in patients treated with tamoxifen suggests that the drug promotes endometrial growth and that endometrial polyps may be an important intermediate step in endometrial carcinogenesis. ( Figure 4 The range of epithelial metaplasias seen in tamoxifen-associated benign endometrial polyps included (A) squamoid metaplasia. A range of endometrial findings was seen in the symptomatic patients treated with tamoxifen. Endometria from two of the three women treated with progestogen showed stromal decidualisation with no other major pathological findings; both these women had received very low doses of tamoxifen. The remaining 15 symptomatic women treated with tamoxifen had pathological abnormalities of the endometrium which fell into two main categories: benign endometrial polyps occurring on a background of endometrial hyperplasia; and primary endometrial malignancies.
Eleven patients had benign endometrial polyps (fig 2) which ranged in size from 1-5 cm to 16 cm (mean 5 cm). Four women had multiple polyps either synchronously or metachronously. The polyps occurred on a background of simple endometrial hyperplasia in six of eight instances where background endometrium was available for assessment. Microscopically, the polyps were characterised by patchy periglandular condensation of stroma (fig 3A) , proliferative activity in epithelial and stromal cells (fig 3B) , and an admixture of epithelial metaplasias including squamoid (fig 4A) , papillary oxyphil cell ( fig  4B), apocrine (fig 4C), and mucinous (fig 4D) metaplasias. Periglandular stromal condensation, proliferative activity, and epithelial metaplasias coexisted in 12 of 15 benign endometrial polyps in this group of patients. The remaining three benign endometrial polyps, all from a patient treated with progestogen (case 11) lacked proliferative activity but did show periglandular stromal condensation and epithelial metaplasias. In contrast, a consecutive series of 40 endometrial polyps of the usual type revealed no instances in which these three microscopic features coexisted in the same polyp.
Altogether there were five endometrial malignancies associated with tamoxifen. One of these was an adenocarcinoma of the endometrium with sarcomatous areas (carcinosarcoma) and another a well differentiated endometrial carcinoma; in both, the tumour showed extensive myometrial infiltration. In three additional cases a superficial endometrial carcinoma ( fig 5) confined to the endometrium occurred within an endometrial polyp. The background endometrium in these uteri with superficial endometrial carcinoma showed cystic hyperplasia with benign polyps (fig 5) . The background benign polyps in these cases were characterised by hyperplasia with varying degrees of cytological atypia as well as focal periglandular stromal condensation and epithelial metaplasias. Figure 6 summarises the correlation between endometrial pathology, tamoxifen dose, and duration of treatment. The patient (case 5) , who initially presented with postmenopausal bleeding from an endometrial polyp and who subsequently was found to have an endometrial polyp-cancer at necropsy, features twice in this figure. Primary endometrial malignancy occurred in patients treated either with 20 mg or 40 mg tamoxifen daily. However, the tumours in the former group developed after a longer period of treatment than those occurring in patients treated with the higher daily dose. All five primary endometrial malignancies occurred in women who had taken a cumulative tamoxifen dose of more than 35 g. Of the remaining six women who had received tamoxifen in excess of this threshold dose, four had benign endometrial polyps and two had generalised endometrial hyperplasia.
Discussion
This study has revealed a spectrum of proliferative abnormalities among women treated with tamoxifen, comprising generalised simple endometrial hyperplasia in the two asymptomatic patients and hyperplasia with polyps, polyp-cancers, or primary invasive malignancies in the symptomatic patients. The control group of women showed a much lower incidence of endometrial polyps, no endometrial polyp-cancers, and a higher incidence of "no endometrial abnormality".
It is at first sight surprising to find proliferative endometrial abnormalities in women treated with tamoxifen as the drug, used for its oestrogen antagonist effects in breast carcinoma, might be expected to exert similar effects on the endometrium with consequent inhibition of endometrial growth. However, tamoxifen exerts a well documented oestrogen-like effect on cervico-vaginal squamous epithelial differentiation in postmenopausal women.5 Previous observations,81' 13 which suggested a similar oestrogen-like effect on the postmenopausal endometrium, have been supported by a recent study9 which found that breast cancer patients treated with the drug had a thicker endometrium than untreated controls, on transvaginal sonography, and a lower incidence of atrophic endometrium on hysteroscopy. The occurrence, in the present study, of proliferative endometrial abnormalities in all but two treated women (both of The development of endometrial malignancy may be promoted by the growth stimulating effect of the drug acting in concert with a genotoxic stimulus. Tamoxifen is a hepatic carcinogen in rats"5 and has been shown to exert a dose dependent genotoxic effect on rat liver,'6 17 as well as in human lyphoblastoid cell lines. ' '9 and their occurrence in these uteri treated with tamoxifen could therefore be attributed to the oestrogen-like effect of tamoxifen.
The importance of the periglandular stromal condensation is uncertain, but this finding raised the possibility that these polyps may represent Mullerian adenosarcomas. However, the patchy nature of this stromal change, the relative paucity of mitotic activity, and absence of cytological atypia and atypical mitoses in the tamoxifen-associated polyps was thought to militate against a diagnosis of Miillerian adenosarcoma.
The occurrence of three endometrial polypcancers in this relatively small group of women treated with tamoxifen was unexpected as these lesions are otherwise extremely rare. Although no precise figures for incidence are available, only four polypcancers were noted in a study of 1100 endometrial polyps. 20 The high prevalence of these rare lesions in this study population can only be explained by a sustained stimulus which favours the development of malignancy in endometrial polyps; the only candidate for this role, in this group of patients, is tamoxifen.
The polyp-cancers in this group of women occurred on a background of endometrial hyperplasia and multiple polyps showing a variable degree of atypical hyperplasia of their epithelial elements. These observations suggest that endometrial polypogenesis may form an important, perhaps essential, intermediate stage between simple endometrial hyperplasia and endometrial malignancy. I suggest that in susceptible patients simple endometrial hyperplasia is followed by endometrial polyps, atypical endometrial hyperplasia, and carcinoma. This proposed sequence of events agrees with the reported risk of subsequent endometrial carcinoma of 04-1% for simple endometrial hyperplasia,"2 3*5% for polyps,2 and 23% for atypical hyperplasia." The factors which influence an individual's susceptibility to this sequence of events are poorly understood. However, tamoxifen is clearly not the only important factor involved as, of the three women who received the highest cumulative dose of the drug, two had simple hyperplasia, one had multiple polyps, and none had a malignancy. An inherited predisposition to endometrial polyps or carcinoma, or both, may also be a factor.
The cancers in the present study were confined to women who had received a total tamoxifen dose in excess of 35 g, irrespective of the daily dose of the drug. This observation suggests that the development of endometrial cancer in women treated with tamoxifen is related not to the daily dose of the drug but to the total dose taken, and that there is a threshold dose above which symptomatic patients have a high risk of an underlying endometrial carcinoma. The existence of this dose threshold, with the implication that women receiving the lower daily dose of the drug will develop endometrial carcinoma after a longer period of treatment, may explain the disparities in the reported incidence of endometrial carcinoma between the higher dose Stockholm trial'0 and trials using the lower daily dose.2425 If such a dose threshold is oper ative, an increase in the incidence of endometrial carcinoma among women receiving the lower daily dose would only become evident on follow up in excess of five years. 
